Upregulation of urokinase in alveolar macrophages and lung tissue in response to silica particles

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 274, Issue 6 18-6, 1998, Pages

  Lardot, Cécile ^a,c   Delos, Monique ^b   Lison, Dominique ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^c Indust Toxicol and Occup Med U   (Belgium)

Author keywords

Fibrosis; Immunohistochemistry; Mouse; Neutrophil depletion

Indexed keywords

AMILORIDE; BETA ACTIN; CYCLOPHOSPHAMIDE; MESSENGER RNA; PLASMIN; PLASMINOGEN ACTIVATOR; SILICON DIOXIDE; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLITIS; LUNG ALVEOLUS CELL; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; LUNG LAVAGE; MOUSE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL;

EID: 0031745405     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.1998.274.6.l1040     Document Type: Article

References (39)

1. Bailie, M. B., J. A. Hewett, A. E. Schultze, and R. A. Roth. Methylene dianiline hepatotoxicity is not leukocyte-dependent. Toxicol. Appl. Pharmacol. 124: 25-30, 1994.
2. Bar Ner, M., M. Mayer, V. Schirrmacher, and I. Vlodavsky. Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix. J. Cell. Physiol. 128: 299-306, 1986.
3. Bertozzi, P., B. Astedt, L. Zenzius, K. Lynch, F. LeMaire, W. Zapol, and H. A. Chapman, Jr. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N. Engl. J. Med. 322: 890-897, 1990.
4. Cantin, A., C. Allard, and R. Begin. Increased alveolar plasminogen activator in early asbestosis. Am. Rev. Respir. Dis. 139: 604-609, 1989.
5. Chapman, H. A., C. L. Allen, and O. L. Stone. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am. Rev. Respir. Dis. 133: 437-443, 1986.
6. Eitzman, D. T., R. D. McCoy, X. Zheng, W. P. Fay, T. Shen, D. Ginsburg, and R. H. Simon. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 97: 232-237, 1996.
7. Falcone, D. J., T. A. McCaffrey, A. Haimovitz Friedman, and M. Garcia. Transforming growth factor-beta 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor. J. Cell. Physiol. 155: 595-605, 1993.
8. Gross, T. J., S. M. Cobb, D. C. Gruenert, and M. W. Peterson. Asbestos exposure increases human bronchial epithelial cell fibrinolytic activity. Am. J. Physiol. 264 (Lung Cell. Mol. Physiol. 8): L276-L283, 1993.
9. Gross, T. J., R. H. Simon, C. J. Kelly, and R. G. Sitrin. Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase. Am. J. Physiol. 260 (Lung Cell. Mol. Physiol. 4): L286-L295, 1991.
10. Gyetko, M. R., R. F. Todd III, C. C. Wilkinson, and R. G. Sitrin. The urokinase receptor is required for human monocyte chemotaxis in vitro. J. Clin. Invest. 93: 1380-1387, 1994.
11. Hamilton, J. A., G. Vairo, K. R. Knight, and B. G. Cocks. Activation and proliferation signals in murine macrophages. Biochemical signals controlling the regulation of macrophage urokinase-type plasminogen activator activity by colony-stimulating factors and other agents. Blood 77: 616-627, 1991.
12. Hart, D. A., P. Whidden, F. Green, J. Henkin, and D. E. Woods. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin. Invest. Med. 17: 69-76, 1994.
13. Huaux, F., J. Louahed, B. Hudspith, C. Meredith, M. Delos, J. C. Renault, and D. Lison. Role of interleukin-10 (IL-10) in the lung response to silica in mice. Am. J. Respir. Cell Mol. Biol. 8: 51-59, 1998.
14. Kanekal, S., L. Fraiser, and J. P. Kehrer. Pharmacokinetics, metabolic activation, and lung toxicity of cyclophosphamide in C57/B16 and ICR mice. Toxicol. Appl. Pharmacol. 114: 1-8, 1992.
15. Khalil, N., S. Corne, C. Whitman, and H. Yacyshyn. Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am. J. Respir. Cell Mol. Biol. 15: 252-259, 1996.
16. Lardot, C., M. Heusterpreute, P. Mertens, M. Philippe, and D. Lison. Expression of plasminogen activator inhibitors type-1 and type-2 (PAI-1 and PAI-2) in the mouse lung after administration of crystalline silica. Eur. Resp. J. In press.
17. Lardot, C., F. Huaux, F. Broeckaert, P. J. Declerck, M. Delos, B. Fubini, and D. Lison. Role of urokinase in the fibrogenic response of the lung to mineral particles. Am. J. Resp. Crit. Care Med. 57: 617-628, 1998.
18. Larsson, L. I., L. Skriver, L. S. Nielsen, J. Grondahl Hansen, P. Kristensen, and K. Dano. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J. Cell Biol. 98: 894-903, 1984.
19. Leavell, K. J., M. W. Peterson, and T. J. Gross. The role of fibrin degradation products in neutrophil recruitment to the lung. Am. J. Respir. Cell Mol. Biol. 14: 53-60, 1996.
20. Levi, M., D. Roem, A. M. Kamp, J. P. de Boer, C. E. Hack, and J. W. ten Cate. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb. Haemost. 69: 141-146, 1993.
21. Lison, D., F. Raguzzi, and R. Lauwerys. Induction of macrophage plasminogen activator by asbestos is independent of PKC activation. Arch. Toxicol. 65: 386-389, 1991.
22. Marshall, B. C., Q. P. Xu, N. V. Rao, B. R. Brown, and J. R. Hoidal. Pulmonary epithelial cell urokinase-type plasminogen activator. Induction by interleukin-1 beta and tumor necrosis factor-alpha. J. Biol. Chem. 267: 11462-11469, 1992.
23. Matsushima, K., M. Taguchi, E. J. Kovacs, H. A. Young, and J. J. Oppenheim. Intracellular localization of human monocyte associated interleukin 1 (IL 1) activity and release of biologically active IL 1 from monocytes by trypsin and plasmin. J. Immunol. 136: 2883-2891, 1986.
24. Mizukami, I. F., N. E. Faulkner, M. R. Gyetko, R. G. Sitrin, and R. F. Todd III. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 86: 203-211, 1995.
25. Moser, T. L., J. J. Enghild, S. V. Pizzo, and M. S. Stack. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem. J. 307: 867-873, 1995.
26. Nanbu, R., P. A. Menoud, and Y. Nagamine. Multiple instability-regulating sites in the 3′ untranslated region of the urokinase-type plasminogen activator mRNA. Mol. Cell. Biol. 14: 4920-4928, 1994.
27. O'Connor, C. M., and M. X. FitzGerald. Matrix metalloproteases and lung disease. Thorax 49: 602-609, 1994.
28. Piguet, P. F., M. A. Collart, G. E. Grau, A. P. Sappino, and P. Vassalli. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 344: 245-247, 1990.
29. Plesner, T., M. Ploug, V. Ellis, E. Ronne, G. Hoyer Hansen, M. Wittrup, T. L. Pedersen, T. Tscherning, K. Dano, and N. E. Hansen. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 83: 808-815, 1994.
30. Robinson, B. W. Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease. Thorax 43: 508-515, 1988.
31. Schnyder, J., R. Marti, P. H. Cooper, and T. G. Payne. Spectrophotometric method to quantify and discriminate urokinase and tissue-type plasminogen activators. Anal. Biochem. 200: 156-162, 1992.
32. Seeger, W., G. Stohr, H. R. Wolf, and H. Neuhof. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J. Appl. Physiol. 58: 326-338, 1985.
33. Shetty, S., A. Kumar, A. R. Johnson, S. Pueblitz, D. Holiday, G. Raghu, and S. Idell. Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. Am. J. Respir. Cell Mol. Biol. 15: 78-87, 1996.
34. Stack, M. S., and D. A. Johnson. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J. Biol. Chem. 269: 9416-9419, 1994.
35. Vassalli, J. D., and D. Belin. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 214: 187-191, 1987.
36. Vassalli, J. D., A. P. Sappino, and D. Belin. The plasminogen activator/plasmin system. J. Clin. Invest. 88: 1067-1072, 1991.
37. Vassalli, J. D., A. Wohlwend, and D. Belin. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system. Curr. Top. Microbiol. Immunol. 181: 65-86, 1992.
38. Waltz, D. A., L. Z. Sailor, and H. A. Chapman. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J. Clin. Invest. 91: 1541-1552, 1993.
39. Williams, A. O., K. C. Flanders, and U. Saffiotti. Immunohistochemical localization of transforming growth factor-beta 1 in rats with experimental silicosis, alveolar type II hyperplasia, and lung cancer. Am. J. Pathol. 142: 1831-1840, 1993.